Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

GlaxoSmithKline plc : 'Patent box' encourages GSK to invest $330 mln more in UK

12/10/2013 | 07:41pm US/Eastern

GlaxoSmithKline is to invest another 200 million pounds ($330 million) on advanced manufacturing in Britain, the company said on Wednesday, underlining the draw of a tax break designed to encourage research and development.

Britain's so-called "patent box" scheme, which offers a reduced rate of corporation tax on income derived from patents, has been hailed by GSK, its biggest drugmaker, for transforming the country as a place to invest.

Last year GSK announced it was building its first new factory in Britain for 40 years as a result of the scheme. The latest move will help it ramp up output of new lung drug Relvar, produce the long-established antibiotic Augmentin and develop innovative technologies for medicine production.

Britain's health minister, Jeremy Hunt, welcomed the new investment. But not all Britain's European partners are as enthusiastic about such patent box arrangements.

In July Germany called for a ban on these schemes, saying they created unfair competition. Patent boxes also operate in the Netherlands and some other European Union member states.

(Reporting by Ben Hirschler; Editing by Greg Mahlich)

Recommend :
React to this article
56m ago GLAXOSMITHKLINE : GSK and Genmab receive FDA approval for Arzerra® (ofatumumab) ..
3h ago China's new breed of whistleblowers takes on big business
7h ago GLAXOSMITHKLINE : GSK announces approval in Canada for Incruse™ Ellipta&tr..
8h agoDJGLAXOSMITHKLINE : GSK Says Incruse Gets Approval in Canada for Treatment of Lung..
8h ago GLAXOSMITHKLINE : GSK announces approval in Canada for Incruse Ellipta (umeclidi..
8h ago GLAXOSMITHKLINE : GSK receives approval in Canada for Incruse
9h ago GLAXOSMITHKLINE : Glaxo COPD Treatment Incruse Ellipta Cleared In Canada
13h ago GSK, facing bribery claims, battles to build new sales model
14h ago GLAXOSMITHKLINE : Glaxo Confirms Investigations In Jordan, Lebanon Operations
19h ago GLAXOSMITHKLINE : Fresh bribery claims hit Glaxo
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Income Statement Evolution
GlaxoSmithKline plc : Income Statement Evolution
More Financials
Dynamic quotes